Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

100.34USD
27 Mar 2015
Change (% chg)

$0.20 (+0.20%)
Prev Close
$100.14
Open
$100.46
Day's High
$100.95
Day's Low
$100.15
Volume
2,198,610
Avg. Vol
2,637,225
52-wk High
$109.49
52-wk Low
$95.10

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being.... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $279,001.31
Shares Outstanding(Mil.): 2,780.56
Dividend: 0.70
Yield (%): 2.79

Financials

  JNJ.N Industry Sector
P/E (TTM): 17.60 40.31 40.78
EPS (TTM): 5.70 -- --
ROI: 15.32 16.86 16.19
ROE: 22.70 17.40 17.04
Search Stocks

Pharmacyclics cancer drug successful as combination therapy: independent panel

- An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

16 Mar 2015

UPDATE 1-Pharmacyclics cancer drug successful as combination therapy - independent panel

March 16 - An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

16 Mar 2015

CORRECTED-Independent panel recommends unblinding study after Imbruvica shows clear benefit

March 16 - An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful in treating two types of cancer in combination with other drugs.

16 Mar 2015

Johnson & Johnson sues Glaxo over allergy ads as spring nears

NEW YORK - Johnson & Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States.

12 Mar 2015

Johnson & Johnson sues Glaxo over allergy ads as spring nears

NEW YORK - Johnson & Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States.

12 Mar 2015

Johnson & Johnson sues Glaxo over allergy ads as spring nears

NEW YORK, March 12 - Johnson & Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States.

12 Mar 2015

Tylenol maker to pay $25 mln for selling metal-contaminated drugs

WASHINGTON - A Johnson & Johnson subsidiary pleaded guilty on Tuesday to selling liquid medicine contaminated with metal and agreed to pay $25 million to resolve the case, the U.S. Department of Justice said on Tuesday.

10 Mar 2015

Tylenol maker to pay $25 million for selling metal-contaminated drugs

WASHINGTON - A Johnson & Johnson subsidiary pleaded guilty on Tuesday to selling liquid medicine contaminated with metal and agreed to pay $25 million to resolve the case, the U.S. Department of Justice said on Tuesday.

10 Mar 2015

Tylenol maker to pay $25 mln for selling metal-contaminated drugs

WASHINGTON, March 10 - A Johnson & Johnson subsidiary pleaded guilty on Tuesday to selling liquid medicine contaminated with metal and agreed to pay $25 million to resolve the case, the U.S. Department of Justice said on Tuesday.

10 Mar 2015

J&J's Ethicon settles bellwether mesh case mid-trial in West Virginia

- Four days into a bellwether trial in West Virginia federal court, Johnson & Johnson's Ethicon Inc has reached a settlement in a lawsuit from a woman who said she was injured by one of its transvaginal mesh devices.

09 Mar 2015

Earnings vs. Estimates

Search Stocks